Dr. Van Morris on Nivolumab as a Potential Treatment for Patients With Anal Cancer

Video

Van K. Morris, MD, assistant professor of GI Oncology, The University of Texas MD Anderson Cancer Center, discusses a study examining nivolumab (Opdivo) as a potential treatment for patients with anal cancer.

Van K. Morris, MD, assistant professor of GI Oncology, The University of Texas MD Anderson Cancer Center, discusses a study examining nivolumab (Opdivo) as a potential treatment for patients with anal cancer.

In a study looking at pretreated patients with metastatic anal cancer, researchers at The University of Texas MD Anderson Cancer Center examined the efficacy of single-agent nivolumab. Responses were seen in 5 of 18 patients—a 28% overall response rate. Of the 18 patients, 9 provided paired biopsies.

Patients who responded to nivolumab were found to have higher levels of CD8-positive and granzyme B cells at baseline. Although this is a small study, the increased levels of activated T cells suggests a response to nivolumab. Additionally, patients who responded were found to have higher levels of PD-1/PD-L1.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD